The pipeline of products under review at FDA refilled in the past week after FDA's July 24 approvals jamboree, with submissions for products ranging from Merck & Co. Inc.'s problem-plagued anesthesia reversal agent to novel biologics for bleeding and immune disorders to new formulations of ADHD medications and the opioid overdose treatment naloxone.
FDA also continued issuing "breakthrough" therapy designations at a steady pace, with recently announced designations including a radiotherapeutic for rare...